Literature DB >> 16817866

Clearance and prevention of prion infection in cell culture by anti-PrP antibodies.

Joanna Pankiewicz1, Frances Prelli, Man-Sun Sy, Richard J Kascsak, Regina B Kascsak, Daryl S Spinner, Richard I Carp, Harry C Meeker, Marcin Sadowski, Thomas Wisniewski.   

Abstract

Prion diseases are transmissible and invariably fatal neurodegenerative disorders associated with a conformational transformation of the cellular prion protein (PrP(C)) into a self-replicating and proteinase K (PK)-resistant conformer, scrapie PrP (PrP(Sc)). Humoral immunity may significantly prolong the incubation period and even prevent disease in murine models of prionoses. However, the mechanism(s) of action of anti-PrP monoclonal antibodies (Mabs) remain(s) obscure. The murine neuroblastoma N2a cell line, infected with the 22L mouse-adapted scrapie strain, was used to screen a large library of Mabs with similar binding affinities to PrP, to identify those antibodies which could clear established infection and/or prevent infection de novo. Three Mabs were found capable of complete and persistent clearing of already-infected N2a cells of PrP(Sc). These antibodies were 6D11 (generated to PK-resistant PrP(Sc) and detecting PrP residues 93-109), and 7H6 and 7A12, which were raised against recombinant PrP and react with neighbouring epitopes of PrP residues 130-140 and 143-155, respectively. Mabs were found to interact with PrP(Sc) formation both on the cell surface and after internalization in the cytosol. Treatment with Mabs was not associated with toxicity nor did it result in decreased expression of PrP(C). Both preincubation of N2a cells with Mabs prior to exposure to 22L inoculum and preincubation of the inoculum with Mabs prior to infecting N2a cells resulted in a significant reduction in PrP(Sc) levels. Information provided in these studies is important for the rational design of humoral immune therapy for prion infection in animals and eventually in humans.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16817866      PMCID: PMC1779824          DOI: 10.1111/j.1460-9568.2006.04805.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  58 in total

1.  Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state.

Authors:  M Horiuchi; B Caughey
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

2.  Transmission of prions.

Authors:  C Weissmann; M Enari; P-C Klöhn; D Rossi; E Flechsig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-14       Impact factor: 11.205

3.  Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation.

Authors:  K Kaneko; L Zulianello; M Scott; C M Cooper; A C Wallace; T L James; F E Cohen; S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

4.  Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol.

Authors:  Jiyan Ma; Robert Wollmann; Susan Lindquist
Journal:  Science       Date:  2002-10-17       Impact factor: 47.728

5.  Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier.

Authors:  D A Kocisko; S A Priola; G J Raymond; B Chesebro; P T Lansbury; B Caughey
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

6.  Prion protein expression in different species: analysis with a panel of new mAbs.

Authors:  G Zanusso; D Liu; S Ferrari; I Hegyi; X Yin; A Aguzzi; S Hornemann; S Liemann; R Glockshuber; J C Manson; P Brown; R B Petersen; P Gambetti; M S Sy
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

7.  Anti-prion antibodies for prophylaxis following prion exposure in mice.

Authors:  Einar M Sigurdsson; Man-Sun Sy; Ruliang Li; Henrieta Scholtzova; Richard J Kascsak; Regina Kascsak; Richard Carp; Harry C Meeker; Blas Frangione; Thomas Wisniewski
Journal:  Neurosci Lett       Date:  2003-01-23       Impact factor: 3.046

8.  A single hamster PrP amino acid blocks conversion to protease-resistant PrP in scrapie-infected mouse neuroblastoma cells.

Authors:  S A Priola; B Chesebro
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

9.  The mode of anchorage to the cell surface determines both the function and the membrane location of Thy-1 glycoprotein.

Authors:  M C Tiveron; M Nosten-Bertrand; H Jani; D Garnett; E M Hirst; F Grosveld; R J Morris
Journal:  J Cell Sci       Date:  1994-07       Impact factor: 5.285

10.  Endogenous proteolytic cleavage of normal and disease-associated isoforms of the human prion protein in neural and non-neural tissues.

Authors:  A Jiménez-Huete; P M Lievens; R Vidal; P Piccardo; B Ghetti; F Tagliavini; B Frangione; F Prelli
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

View more
  46 in total

1.  Direct evidence of generation and accumulation of β-sheet-rich prion protein in scrapie-infected neuroblastoma cells with human IgG1 antibody specific for β-form prion protein.

Authors:  Toshiya Kubota; Yuta Hamazoe; Shuhei Hashiguchi; Daisuke Ishibashi; Kazuyuki Akasaka; Noriyuki Nishida; Shigeru Katamine; Suehiro Sakaguchi; Ryota Kuroki; Toshihiro Nakashima; Kazuhisa Sugimura
Journal:  J Biol Chem       Date:  2012-02-22       Impact factor: 5.157

2.  In vitro neutralization of prions with PrP(Sc)-specific antibodies.

Authors:  Ryan Taschuk; Jacques Van der Merwe; Kristen Marciniuk; Andrew Potter; Neil Cashman; Philip Griebel; Scott Napper
Journal:  Prion       Date:  2015       Impact factor: 3.931

3.  Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model.

Authors:  Ayodeji A Asuni; Maitea Guridi; Joanna E Pankiewicz; Sandrine Sanchez; Martin J Sadowski
Journal:  Ann Neurol       Date:  2014-04-28       Impact factor: 10.422

4.  Aggregated, wild-type prion protein causes neurological dysfunction and synaptic abnormalities.

Authors:  Roberto Chiesa; Pedro Piccardo; Emiliano Biasini; Bernardino Ghetti; David A Harris
Journal:  J Neurosci       Date:  2008-12-03       Impact factor: 6.167

5.  Highly polar environments catalyze the unfolding of PrP C helix 1.

Authors:  Martin Lingenheil; Robert Denschlag; Paul Tavan
Journal:  Eur Biophys J       Date:  2010-01-05       Impact factor: 1.733

6.  An N-terminal polybasic domain and cell surface localization are required for mutant prion protein toxicity.

Authors:  Isaac H Solomon; Natasha Khatri; Emiliano Biasini; Tania Massignan; James E Huettner; David A Harris
Journal:  J Biol Chem       Date:  2011-03-08       Impact factor: 5.157

Review 7.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

8.  Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration.

Authors:  Magdalena A Kuszczyk; Sandrine Sanchez; Joanna Pankiewicz; Jungsu Kim; Malgorzata Duszczyk; Maitea Guridi; Ayodeji A Asuni; Patrick M Sullivan; David M Holtzman; Martin J Sadowski
Journal:  Am J Pathol       Date:  2013-03-13       Impact factor: 4.307

9.  Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse.

Authors:  Erika Chung; Yong Ji; Yanjie Sun; Richard J Kascsak; Regina B Kascsak; Pankaj D Mehta; Stephen M Strittmatter; Thomas Wisniewski
Journal:  BMC Neurosci       Date:  2010-10-14       Impact factor: 3.288

10.  A novel, drug-based, cellular assay for the activity of neurotoxic mutants of the prion protein.

Authors:  Tania Massignan; Richard S Stewart; Emiliano Biasini; Isaac H Solomon; Valentina Bonetto; Roberto Chiesa; David A Harris
Journal:  J Biol Chem       Date:  2009-11-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.